Following the acquisition as part of a management buy-out in 2011, funds managed by Equistone Partners Europe (Munich, DE / Zurich, CH) sold their majority shareholding in pharmaceutical fine chemicals manufacturer Uetikon Chemie (Lahr, Germany) to Novacap (Lyon, FR) for an undisclosed amount. Novacap is majority owned by Ardian, a Europe-based private equity firm.
For Equistone, the transaction was supported by Novumed Life Science Consulting & Advisory (Commercial Vendor Due Diligence), Lazard (M&A), P+P Pöllath & Partners (Legal), KPMG (Financial & Tax) and Ecosens (Environmental Vendor Due Diligence).
Novumed is an independent strategy consulting & advisory firm with a clear industry focus on pharma, medical technology and diagnostics. In recent years, Novumed has frequently supported major European investors in the acquisition or divestiture of life science assets.